Cohera Medical, Inc.® to Present at 32nd Annual J.P. Morgan Healthcare Conference
PITTSBURGH, Jan. 7, 2014 /PRNewswire/ -- Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical adhesives and sealants, will present at the 32nd Annual J.P. Morgan Healthcare Conference. Patrick Daly, President and Chief Executive Officer, will make a formal presentation on the Company on January 14th at 1:30pm PST.
Mr. Daly will provide an overview of the Company's recent successes related to its TissuGlu® Surgical Adhesive and Sylys® Surgical Sealant. "We are honored to be included in this year's Healthcare Conference," said Daly. "This past year marked important milestones for Cohera and I am looking forward to sharing our progress with the other attendees."
The conference, being held at the Westin St. Francis Hotel in San Francisco from January 13-16, is one of the largest and most informative healthcare investment symposiums in the industry, bringing together global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community. After a pivotal 2013, the opportunity to present at the Healthcare Conference is a testament to the progress Cohera has made and marks the first of many expected milestones in 2014.
About Cohera Medical
Cohera Medical, Inc.® is a leading innovator and developer of absorbable surgical adhesives and sealants. The Company's first product, TissuGlu® Surgical Adhesive, is an internal surgical adhesive for large flap surgeries, such as abdominoplasty (tummy tuck), that eliminates or reduces fluid accumulation and the need for post surgical drains. TissuGlu's chemical composition is resorbable, non-toxic, forms a strong bond between tissue layers and allows for natural healing, which ultimately may enable faster recovery. TissuGlu has received CE Marking approval to be sold in the European Union (EU). Cohera Medical is also developing a unique and proprietary intestinal sealant, and a strong adhesive for mesh fixation. Outside of the EU, TissuGlu and the other Cohera products are currently indicated for investigational use only and have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or in any other market. For more information, visit www.coheramed.com.
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.
SOURCE Cohera Medical, Inc.